Behcet's disease

被引:0
|
作者
Saadoun, D. [1 ,2 ,3 ,4 ]
机构
[1] Hop La Pitie Salpetriere, Dept Med Interne & Immunol Clin, 83,Blvd Hop, F-75013 Paris, France
[2] INSERM, UMR S 959, F-75013 Paris, France
[3] CNRS, FRE3632, F-75005 Paris, France
[4] RHU IMAP, Paris, France
来源
REVUE DE MEDECINE INTERNE | 2023年 / 44卷
关键词
Vasculitis; Behcet's disease; Biotherapiesa; VENOUS THROMBOSIS; MORTALITY;
D O I
10.1016/j.revmed.2023.10.116
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Behcet's disease (BD) is a systemic large-vessel vasculitis characterized by a wide clinical spectrum including recurrent oral and genital ulcerations, uveitis, vascular, neurological, articular, and gastrointestinal manifestations. Therapeutic management of BD depends of the clinical presentation and organ involved. Although colchicine, nonsteroidal antiinflammatory agents and topical treatments with corticosteroidsare often sufficient for mucocutaneous and joint involvement, a more aggressive approach with immunosuppressive agents is warranted for severe manifestations such as posterior uveitis, retinal vasculitis, vascular, neurological and gastrointestinal involvement. However, some patients still have refractory disease, relapses, sight threatening eye disease, or irreversible organ damage. Recent improvements in the understanding of the pathogenic mechanisms have led to the identification of potential targets and future therapies for BD. In contrast to current non-specific immunosuppressive agents, the emergenceof immunomodulatory drugs provides the possibility of interfering with specific pathogenic pathways. Novel targeted immunosuppressive therapies might be used in the future for BD.
引用
收藏
页码:A299 / A301
页数:3
相关论文
共 50 条
  • [21] Gastrointestinal manifestations of Behcet's disease
    Bayraktar, Y
    Özaslan, E
    Van Thiel, DH
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2000, 30 (02) : 144 - 154
  • [22] Cardiovascular involvement in Behcet's disease
    Desbois, A-C
    Wechsler, B.
    Cluzel, P.
    Helft, G.
    Boutin, D.
    Piette, J-C
    Cacoub, P.
    Saadoun, D.
    REVUE DE MEDECINE INTERNE, 2014, 35 (02): : 103 - 111
  • [23] Behcet's disease as a prethrombotic state
    Haznedaroglu, S
    Karaaslan, Y
    Haznedaroglu, IC
    Dundar, SV
    INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, 1998, 28 (03) : 200 - 200
  • [24] ANCA associated with Behcet's disease
    Burrows, NP
    Norris, PG
    Zhao, MH
    Lockwood, CM
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1996, 89 (01) : P47 - P48
  • [25] Venous lesions in Behcet's disease
    Sagdic, K
    Ozer, ZG
    Saba, D
    Ture, M
    Cengiz, M
    EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 1996, 11 (04) : 437 - 440
  • [26] Neuroradiological findings in Behcet's disease
    Kirchhof, K
    Jansen, O
    Sartor, K
    ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 1999, 171 (02): : 155 - 159
  • [27] Vascular involvement in Behcet's disease
    Tazi-Mezalek, Z.
    Ammouri, W.
    Maamar, M.
    REVUE DE MEDECINE INTERNE, 2009, 30 : S232 - S237
  • [28] OVERVIEW ON THE TREATMENT OF BEHCET'S DISEASE
    Miriam, Heredia
    Miguel, Torralba
    Susana, Canales
    ATENCION FARMACEUTICA, 2009, 11 (01): : 42 - 48
  • [29] Macular ischaemia in Behcet's disease
    Yilmaz, G
    Akova, Y
    Aydin, P
    EYE, 2000, 14 (5) : 717 - 720
  • [30] Behcet's disease - Current status
    Sharir, M
    Isakov, I
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2002, 4 (11): : 946 - 948